NCT00477711View on ClinicalTrials.gov

A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

February 28, 2009

Conditions
Gastric Cancer
Interventions
DRUG

cetuximab, cisplatin, capecitabine

Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously

Trial Locations (1)

100036

Peking University,School of Oncology, Gastrointestinal Department, Beijing

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Peking University

OTHER

NCT00477711 - A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter